Nanotechnology for Drug Delivery - Global Market for Nanocarriers

  • ID: 2059352
  • Report
  • Region: Global
  • 108 Pages
  • Cientifica Ltd
1 of 5
Nanocarriers will account for 40% of a $136 billion nanotechnology-enabled drug delivery market by 2021. We forecast the total market size in 2021 to be US$136 billion, with a 60/40 split between nanocrystals and nanocarriers respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs.

Of the 10 nanocarrier technologies studied, liposomes and gold nanocarriers account for 45% of the total addressable market. Liposomes will offer the largest addressable market ($15 billion) in 2021 while gold nanocarriers will see the highest compound annual growth rate (CAGR)—53.8%—in the next decade.

Drugs are loaded into nanocarriers (also called nanoshells or nanoparticles, between 1 and 100 nm), then transported through the body to the target site. This kind of targeted drug delivery for the treatment of cancers is one of the most anticipated and discussed benefits of nanotechnology-enabled medicine as it offers a level of accuracy in delivering drugs that far surpasses present methods. Typically over 90% of a drug is wasted in the body, which leads to unwanted side effects. Modern chemotherapy bombards patients with drugs in the hope that tumorous cells will be destroyed. The lack of specificity of current drug delivery techniques mean patients' healthy cells are destroyed indiscriminately along with cancer cells.

Using nanotechnology to combat cancer is not new. Abraxane, the first nanoparticulate drug delivery product for the treatment of breast cancer, launched six years ago. There are now hundreds of new nanotech-based treatments under development, ranging from reformulation of existing drugs to enhance their efficacy to radical new “magic bullet” therapies.

The healthcare market is changing. We are seeing a paradigm shift away from blockbusters and a ‘one-size fits all' approach to a more personalised medicine based on an individual's unique genome and immune response. The more scientists learn about the molecular causes for disease the more targeted and effective nanotechnology-enabled drug delivery therapies will become.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
TABLE OF EXHIBITS

EXECUTIVE SUMMARY

CHAPTER 1 - INTRODUCTION
REPORT SCOPE
METHODOLOGY
Procurement
Calculation of CAGR
THE NANOSCALE
Two biological examples that illustrate nanoscale:

CHAPTER 2 – NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
OVERVIEW OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
Why is Nanotechnology A Critical Application for Medicine and Biomedicine?
Why Nanotechnology Is Needed for Medicine and Biomedicine
WHAT ARE THE KEY DRIVERS FOR ADOPTION OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE?
The Aim Of Drug Targeting
Rapid Market Growth
Market Drivers For Enhanced Drug Delivery
Increasing Proportion of The Ageing Population
Demand For More Affordable Health Care
Public Health – Ending disease
Demand for More Innovation
Social responsibility
THE KEY APPLICATIONS OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
How Nanotechnology Can Benefit Drug Delivery
Nanotechnology in Medical and Biomedical Diagnostics
Nanotechnology in Regenerative Medicine and Tissue Engineering
Other Applications For Nanomaterials In The Medical And Pharmaceutical Sector
PROMISING EXAMPLES OF NANOTECHNOLOGY ENABLED DRUG DELIVERY
Case Study 1 – Magnetic Field Acts as "Remote Control" to Deliver Nanomedicine
Case Study 2 - Adaptive Micro and Nanoparticles: Temporal Control Over Carrier
Properties to Facilitate Drug Delivery
Case Study 3 – Fabrication of a Nanocarrier System Through Self-Assembly of Plasma
Protein And Its Tumour Targeting
Case Study 4 – IBM And The Institute of Bioengineering And Nanotechnology Find
Breakthrough For MRSA

CHAPTER 3 – RISK & REGULATION
THREE KEY BARRIERS TO THE ADOPTION OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
Nanotoxicity Nanopollution and Nanosafety
Ethical Considerations Of Nanotherapies
Delayed Nanoregulation
FIVE CURRENT & FUTURE CHALLENGES IN THE ADOPTION OF NANOTECHNOLOGY IN
MEDICINE AND BIOMEDICINE
Current & Future Challenges of Nanosafety And Risk Management
Current & Future Challenges of Nanoregulation
Current & Future Challenges for the Nanomedicine Industry
Current & Future Challenges of Sustained Innovation
Current & Future Challenges of Cooperation

CHAPTER 4 – MARKET FOR NANOCARRIERS
GLOBAL MARKET ANALYSIS: 2000-2010 (WITHOUT SEGMENTATION)
GLOBAL MARKET FORECAST: 2011-2021 (WITHOUT SEGMENTATION)
DISCUSSION OF NANOPARTICLES & NANOCARRIERS
Overview of The Key Nanotechnologies Used in Drug Delivery Sorted by Applications
Nanopharmaceuticals
Nanotechnology In Drug Delivery
Nanobiotechnology In Drug Delivery
Analytical Techniques For Nanoparticle Drug Delivery
Properties
Production of Nanoparticles
Measuring Dispersion of Nanoparticles
Characterisation of Carrier Systems
Nanocarriers
Classification of Nanocarriers
Multifunctional Nanocarriers - Drug Delivery And Medical / Biomedical Diagnostics
Nanocarriers as Drug Carriers
What Can Nanoparticles do in Drug Delivery?
Polymer-Based Nanocarriers (Polymeric Nanoparticles)
Lipid-Based Nanocarriers
Organic Nanocarriers
Inorganic Nanocarriers
Disadvantages Associated With Nanocarriers
The Most Relevant Technologies in The Key Area of Nanotechnology in Drug Delivery
Stage of Development of Key Nanotechnologies Used in Drug Delivery
Clinically Approved Nanocarrier-Based Drug Formulations With Presence on The Market
The First Nanoparticle Drug Delivery System Reaches The Market
Present And Future Applications
TECHNOLOGY ADOPTION ROADMAP
Projected Product Pipeline For Nanocarrier-Based Drug Formulations In Drug Delivery Market
Available Applications Of Nanoparticles In Drug Delivery
Semapimod® (cytokine, pharmasciences)
Paxceed™
Theralux™
Nucryst®
iSPERSE™
ANALYSIS OF TAM FOR NANOCARRIERS: 2000-2010
TAM FORECAST FOR NANOCARRIERS: 2011-2021

APPENDIX 1
PUBLISHING ACTIVITY BY ORGANIZATION (2000-2010)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Nanocarriers set to be 40% of NDD market by 2021

Cientifica sees a 60/40 market split between nanocrystals and nanocarriers

Nanocarriers will account for 40% of a $136 billion nanotechnology-enabled drug delivery market by 2021 according to new research published by Cientifica in its report, Nanotechnology for Drug Delivery: Global Market for Nanocarriers.

“We forecast the total market size in 2021 to be US$136 billion, with a 60/40 split between nanocrystals and nanocarriers respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs,” said Tim Harper, CEO of Cientifica Ltd.

Of the 10 nanocarrier technologies studied, liposomes and gold nanocarriers account for 45% of the total addressable market. Liposomes will offer the largest addressable market ($15 billion) in 2021 while gold nanocarriers will see the highest compound annual growth rate (CAGR)—53.8%—in the next decade.

Drugs are loaded into nanocarriers (also called nanoshells or nanoparticles, between 1 and 100 nm), then transported through the body to the target site. This kind of targeted drug delivery for the treatment of cancers is one of the most anticipated and discussed benefits of nanotechnology-enabled medicine as it offers a level of accuracy in delivering drugs that far surpasses present methods. Typically over 90% of a drug is wasted in the body, which leads to unwanted side effects. Modern chemotherapy bombards patients with drugs in the hope that tumorous cells will be destroyed. The lack of specificity of current drug delivery techniques mean patients' healthy cells are destroyed indiscriminately along with cancer cells.

“It's the equivalent of using a nuclear bomb to eliminate just a handful of enemies,” said Harper. “In theory, as long as the nanocarrier is designed specifically enough, it should be possible to deliver all of the drug to the target site whilst leaving healthy cells unaffected. This greatly reduces treatment time, costs and unwanted side effects.”

Using nanotechnology to combat cancer is not new. Abraxane, the first nanoparticulate drug delivery product for the treatment of breast cancer, launched six years ago. There are now hundreds of new nanotech-based treatments under development, ranging from reformulation of existing drugs to enhance their efficacy to radical new “magic bullet” therapies.

“The healthcare market is changing. We are seeing a paradigm shift away from blockbusters and a ‘one-size fits all' approach to a more personalised medicine based on an individual's unique genome and immune response. The more scientists learn about the molecular causes for disease the more targeted and effective nanotechnology-enabled drug delivery therapies will become,” said Harper.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll